We are live on
!
Find out more
Vir Biotechnology
211 hedge funds and large institutions have $2.2B invested in Vir Biotechnology in 2022 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 75 increasing their positions, 56 reducing their positions, and 42 closing their positions.
New
Increased
Maintained
Reduced
Closed
74% more call options, than puts
Call options by funds: $11.6M | Put options by funds: $6.66M
34% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 56
21% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 42
5% more capital invested
Capital invested by funds: $2.09B → $2.2B (+$113M)
3.5% more ownership
Funds ownership: 61.33% → 64.83% (+3.5%)
3% more funds holding
Funds holding: 204 → 211 (+7)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Holders
211
Holders Change
+7
Holders Change %
+3.43%
% of All Funds
3.55%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
51
Increased
75
Reduced
56
Closed
42
Calls
$11.6M
Puts
$6.66M
Net Calls
+$4.9M
Net Calls Change
-$1.5M
Top Buyers
| 1 |
BlackRock
New York
|
+$173M |
| 2 |
State Street
Boston,
Massachusetts
|
+$30.9M |
| 3 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$18.3M |
| 4 |
Morgan Stanley
New York
|
+$11.4M |
| 5 |
Renaissance Technologies
New York
|
+$10.9M |
